Free Trial

Cencora, Inc. (NYSE:COR) Given Average Recommendation of "Moderate Buy" by Brokerages

Cencora logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst consensus: Cencora has an average rating of "Moderate Buy" from 15 analysts (12 buy, 3 hold) with an average 12‑month price target of $398.17.
  • Recent results: The company reported quarterly EPS of $4.08 (beat $4.04) while revenue of $85.93B slightly missed expectations, but revenue was up 5.5% year‑over‑year and analysts project ~17.56 EPS for the year.
  • Market and income profile: Shares opened at $304.18 with a 52‑week range of $271–$377.54, a market cap of $59.17 billion and a P/E of 36.56; the company pays a quarterly dividend of $0.60 (annual $2.40, yield ~0.8%) and institutional investors own ~97.5% of the stock.
  • Interested in Cencora? Here are five stocks we like better.

Cencora, Inc. (NYSE:COR - Get Free Report) has earned an average rating of "Moderate Buy" from the fifteen analysts that are presently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and twelve have given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $398.1667.

Several analysts have recently weighed in on the stock. Leerink Partners reissued an "outperform" rating on shares of Cencora in a research note on Tuesday, March 17th. William Blair assumed coverage on shares of Cencora in a research note on Tuesday, April 28th. They issued a "market perform" rating for the company. Morgan Stanley set a $380.00 price target on shares of Cencora in a research note on Tuesday, March 17th. Evercore set a $360.00 price target on shares of Cencora in a research note on Wednesday, April 8th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Cencora from $417.00 to $419.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 10th.

Check Out Our Latest Stock Analysis on COR

Cencora Stock Performance

Cencora stock opened at $304.18 on Monday. The firm has a 50 day simple moving average of $333.36 and a 200-day simple moving average of $343.31. Cencora has a 1-year low of $271.00 and a 1-year high of $377.54. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.51. The stock has a market cap of $59.17 billion, a price-to-earnings ratio of 36.56, a price-to-earnings-growth ratio of 1.42 and a beta of 0.64.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, beating the consensus estimate of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The business had revenue of $85.93 billion during the quarter, compared to analysts' expectations of $86.12 billion. During the same quarter in the prior year, the company posted $3.73 EPS. The business's revenue for the quarter was up 5.5% on a year-over-year basis. On average, analysts expect that Cencora will post 17.56 EPS for the current year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Investors of record on Friday, February 13th were given a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, February 13th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.8%. Cencora's dividend payout ratio (DPR) is presently 28.85%.

Hedge Funds Weigh In On Cencora

A number of hedge funds have recently made changes to their positions in the stock. United Bank boosted its position in shares of Cencora by 4.5% during the 1st quarter. United Bank now owns 7,676 shares of the company's stock worth $2,411,000 after purchasing an additional 332 shares during the period. Diversify Wealth Management LLC purchased a new position in shares of Cencora during the 1st quarter worth approximately $1,183,000. Valmark Advisers Inc. boosted its position in shares of Cencora by 21.2% during the 1st quarter. Valmark Advisers Inc. now owns 1,428 shares of the company's stock worth $449,000 after purchasing an additional 250 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in shares of Cencora by 0.5% during the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 45,315 shares of the company's stock worth $14,235,000 after purchasing an additional 218 shares during the period. Finally, Ferguson Wellman Capital Management Inc. boosted its position in shares of Cencora by 0.8% during the 1st quarter. Ferguson Wellman Capital Management Inc. now owns 212,070 shares of the company's stock worth $66,620,000 after purchasing an additional 1,582 shares during the period. Hedge funds and other institutional investors own 97.52% of the company's stock.

Cencora Company Profile

(Get Free Report)

Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

See Also

Analyst Recommendations for Cencora (NYSE:COR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Cencora Right Now?

Before you consider Cencora, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.

While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines